专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20210361663A1 Formulations of Antiviral Compounds 有权
公开(公告)号：US20210361663A1
公开(公告)日：2021-11-25
申请号：US17286620
申请日：2019-10-21
申请人： Sutthilug SOTTHIVIRAT , Joyce STELLABOTT , Walter R. WASYLASCHUK , Merck Sharp & Dohme Corp.
发明人： Sutthilug Sotthivirat , Joyce Stellabott , Walter R. Wasylaschuk
IPC分类号： A61K31/5365 , A61K9/20
摘要： The present disclosure is directed to pharmaceutical formulations comprising an amorphous inhibitor of hepatitis C vims NS5A. These pharmaceutical formulations may be prepared by roller-compaction or wet-granulation methods. The present disclosure is also directed to oral dosage forms, such as tablets, comprising such pharmaceutical formulations.

2. 发明授权

US10167298B2 Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof 有权
公开(公告)号：US10167298B2
公开(公告)日：2019-01-01
申请号：US15032663
申请日：2014-10-24
申请人： MERCK SHARP & DOHME CORP.
发明人： Michael McNevin , Yong Liu , Ian Mangion , Alfred Lee , Joyce Stellabott , Benjamin D. Sherry , Gary Martin , Kung-I Feng , Scott Schultz , Ryan Cohen , Yanfeng Zhang
IPC分类号： A61K31/5365 , C07D498/04 , A61P1/16 , A61K45/06
摘要： The present invention relates to novel Pseudopolymorphs of Compound A, compositions comprising at least one Pseudopolymorph of Compound A, and methods of using the Pseudopolymorphs of Compound A for preparing compositions useful for treating or preventing HCV infection in a patient, wherein Compound A has the structure.

3. 发明申请

US20070129548A1 Polymorphs of an androgen receptor modulator 失效
标题翻译：雄激素受体调节剂的多态性
公开(公告)号：US20070129548A1
公开(公告)日：2007-06-07
申请号：US11633152
申请日：2006-12-04
申请人： Lushi Tan , Robert Meissner , Wenjie Li , James Perkins , Aaron Cote , Joyce Stellabott , Yuan-Hon Kiang
发明人： Lushi Tan , Robert Meissner , Wenjie Li , James Perkins , Aaron Cote , Joyce Stellabott , Yuan-Hon Kiang
IPC分类号： A61K31/4745 , C07D471/02
CPC分类号： C07J73/005 , C07D471/04
摘要： Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
摘要翻译：结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤手术，肌营养不良，虚弱，老化的皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。

4. 发明授权

US07365202B2 Polymorphs of an androgen receptor modulator 失效
标题翻译：雄激素受体调节剂的多态性
公开(公告)号：US07365202B2
公开(公告)日：2008-04-29
申请号：US11633152
申请日：2006-12-04
申请人： Lushi Tan , Robert S. Meissner , Wenjie Li , James J. Perkins , Aaron S. Cote , Joyce Stellabott , Yuan-Hon Kiang
发明人： Lushi Tan , Robert S. Meissner , Wenjie Li , James J. Perkins , Aaron S. Cote , Joyce Stellabott , Yuan-Hon Kiang
IPC分类号： C07D221/18
CPC分类号： C07J73/005 , C07D471/04
摘要： Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer's disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.
摘要翻译：结构式I的化合物是以组织选择性方式的雄激素受体（AR）的调节剂。这些化合物可用于增强弱化肌张力和治疗由雄激素缺乏引起的疾病或可由雄激素给药改善的疾病，包括骨质疏松症，骨质减少，糖皮质激素诱导的骨质疏松症，牙周病，骨折，骨重建后的骨损伤手术，肌营养不良，虚弱，老化的皮肤，男性性腺机能减退，女性绝经后症状，动脉粥样硬化，高胆固醇血症，高脂血症，肥胖，再生障碍性贫血和其他造血障碍，炎性关节炎和关节修复，艾滋病毒消耗，前列腺癌，良性前列腺增生），腹部肥胖，代谢综合征，II型糖尿病，癌症恶病质，阿尔茨海默氏病，肌营养不良症，认知衰退，性功能障碍，睡眠呼吸暂停，抑郁症，卵巢早衰以及自身免疫性疾病，单独或与其它活性剂组合。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式